Full Press Release Details
IM Cannabis to Launch WAGNERS Brand in Germany
IM Cannabis expects to export premium, indoor-grown Canadian
cannabis in 2022 to the rapidly evolving German medical cannabis
Toronto, Canada; Glil Yam, Israel and Bad Oldesloe, Germany
December 7, 2021 IM Cannabis
Corp. (the Company or IM Cannabis ) (CSE: IMCC, NASDAQ:
IMCC), a global cannabis company with operations in Israel, Canada,
and Germany is pleased to announce plans to launch its popular
Canadian WAGNERS brand in the German medical cannabis market in
2022 and begin exports of premium, indoor-grown dried flower from
IMC Canada's cultivation facility in 2022, subject to
regulatory approval. These plans are consistent with the
Company's vertically integrated, multi-country strategy and
follow the Company's recently announced launch of WAGNERS in
Israel and the receipt of an import permit for Canadian cannabis
products from the Israeli Ministry of Health.
learn more about WAGNERS, please visit WAGNERS - Well Made
Weed (wagnersweed.com)1
Oren Shuster, CEO of IM Cannabis stated, With the
rapid growth in demand for premium indoor-grown Canadian cannabis
and an increasing number of German medical patients not relying on
government re-imbursement, we are excited to launch our popular
WAGNERS brand to medical patients in Germany. We continue to lay
our foundation in Germany, currently one of the largest medical
cannabis markets in the world, which is expected to rapidly expand
as Germany's new elected government enact broad regulatory
reform of cannabis use. Leveraging our global supply chain, IM
Cannabis continues to focus on growing our business substantially
in Germany in the near term and being well-positioned through brand
recognition for eventual regulatory reform.
IM Cannabis' Global Infrastructure for International
Cannabis operates in Germany through Adjupharm GmbH, the
Company's fully licensed EU-GMP subsidiary
which recently completed construction of a new, state-of-the-art
logistics center that will allow the Company to execute all aspects
of its supply chain including the repackaging of bulk cannabis. The
Company expects that the logistics center will augment the
Company's distribution capabilities. Additionally, the
Company's operations in Germany are expected to serve as the
center of a broader long-term European strategy. Since being
acquired by IM Cannabis, Adjupharm has upgraded its production and
storage capacities to meet the increase in medical cannabis volumes
from new supply agreements. With the completion of the logistics
center, IM Cannabis has now doubled its footprint in Germany to
approximately 8,000 square feet, upgraded its production facilities
with state-of-the-art technology, and increased its storage
capacity to seven tons of cannabis. With the logistics center in
operation, new sources of supply extending its portfolio to include
premium products, some of them exclusive, and a wide network of
distribution partners, the Company expects to fortify and grow its
presence in the German market.
Cannabis operates in Canada through Trichome Financial Corp.
its subsidiaries Trichome JWC Acquisition Corp.
Nutraceuticals Inc. ( MYM , and together with Trichome
Canada ). IMC Canada's Manitou Facility in
Kitchener, Ontario is a 115,000 square foot indoor cultivation
facility located just one hour away from Toronto, that has achieved
accreditation as Good Agricultural and Collection Practices
( GACP ) by virtue of its ICann G.A.P certification,
and it serves as the Company's global cultivation hub for
export and further processing in Germany and Israel.
About IM Cannabis Corp.
Cannabis (NASDAQ: IMCC, CSE: IMCC) is a leading international
cannabis company providing premium products to medical patients and
adult-use recreational consumers. IM Cannabis is one of the very
few companies with operations in Israel, Germany, and Canada, the
three largest federally legal markets. The ecosystem created
through its international operations leverages the Company's
unique data-driven perspective and product supply chain globally.
With its commitment to responsible growth and financial prudence,
and the ability to operate within the strictest regulatory
environments, the Company has quickly become one of the leading
cultivators and distributors of high-quality cannabis
Cannabis ecosystem operates in Israel through its commercial
relationship with Focus Medical Herbs, which cultivates, imports,
and distributes cannabis to medical patients, leveraging years of
proprietary data and patient insights. The Company also operates
medical cannabis retail pharmacies, online platforms, distribution
centres and logistical hubs in Israel that enable the safe delivery
and quality control of IM Cannabis products throughout the entire
value chain. In Germany, the IM Cannabis ecosystem operates through
Adjupharm GmbH ( Adjupharm or IMC Germany ), where it also
distributes cannabis to pharmacies for medical patients. In Canada,
IM Cannabis operates through Trichome Financial Corp.
its subsidiaries Trichome JWC Acquisition Corp ( TJAC ) and MYM Nutraceuticals Inc.
together with Trichome and TJAC, IMC Canada ), where it cultivates
and processes cannabis for the adult-use market at its Ontario,
Nova Scotia, and Quebec facilities under the WAGNERS and Highland
Disclaimer for Forward-Looking Statements
press release contains forward-looking information
and forward-looking statements within the meaning of
applicable Canadian and United States securities laws
(collectively, forward-looking information ).
Forward-looking information are often, but not always, identified
by the use of words such as seek ,
anticipate , believe ,
plan , estimate , expect ,
likely and intend and statements that
an event or result may , will ,
should , could or might